Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Jefferam1on Mar 23, 2017 9:47pm

195 Views

Post# 26023706

Zacks

https://scr.zacks.com/Coverage/Biotech-David-Bautz-PhD/default.aspx

I was looking over some of David Bautz picks. I'm kinda disapointed, he doesn't seem to have a good track record.
Although some have done well, most have tanked.
I'm putting a lot less value to article.
I mean I believe Antibe to be worth .50-.75 today and potential to be $4.00+ but that was true before reading his article and hasn't changed.
I just hope more reputable people will cover V.ATE and maybe track some real money.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading